Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: Biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity
Review articleOpen access

AbstractA hitherto unknown class of celecoxib analogs was designed for evaluation as dual inhibitors of the 5-lipoxygenase/cyclooxygenase-2 (5-LOX/COX-2) enzymes. These compounds possess a SO2Me (11a), or SO2NH2 (11b) COX-2 pharmacophore at the para-position of the N1-phenyl ring in conjunction with a 5-LOX N-hydroxypyrid-2(1H)one iron-chelating moiety in place of the celecoxib C-5 tolyl group. The title compounds 11a–b are weak inhibitors of the COX-1 and COX-2 isozymes (IC50 = 7.5–13.2 μM range). In contrast, the SO2Me (11a, IC50 = 0.35 μM), and SO2NH2 (11b, IC50 = 4.9 μM), compounds are potent inhibitors of the 5-LOX enzyme comparing favorably with the reference drug caffeic acid (5-LOX IC50 = 3.47 μM). The SO2Me (11a, ED50 = 66.9 mg/kg po), and SO2NH2 (11b, ED50 = 99.8 mg/kg po) compounds exhibited excellent oral anti-inflammatory (AI) activities being more potent than the non-selective COX-1/COX-2 inhibitor drug aspirin (ED50 = 128.9 mg/kg po) and less potent than the selective COX-2 inhibitor celecoxib (ED50 = 10.8 mg/kg po). The N-hydroxypyridin-2(1H)one moiety constitutes a novel pharmacophore for the design of cyclic hydroxamic mimetics capable of chelating 5-LOX iron for exploitation in the design of 5-LOX inhibitory AI drugs.

Request full text

References (0)

Cited By (0)

No reference data.
No citation data.
Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!